5 articles
Swiss generic drugmaker Sandoz lowered full-year sales guidance to 5-6% but raised core earnings margin forecasts to 23%-23.5% by 2026, citing biosimilar supply constraints that impacted third-quarter
Sandoz's last integrated European penicillin plant faces closure due to low-cost Chinese competition, prompting an EU anti-dumping investigation. The situation highlights critical supply chain vulnera
European shares declined as rising crude oil prices fueled inflation fears, while Novartis stock tumbled following two failed late-stage drug trials. Meanwhile, Sandoz gained ground on ambitious sales
Sandoz filed an anti-dumping complaint with the EU Commission against Chinese amoxicillin imports, citing market-distorting practices. The company warns Europe risks losing antibiotic manufacturing ca
Italy's antitrust authority opened an investigation into Biogen over allegations of abusing its dominant position to exclude rival Sandoz from the multiple sclerosis drug market.
ChemBrief